WCN26-1801 Association Between SGLT2 Inhibitor Use and Mortality in Older Adults with Diabetic Kidney Disease: A Target Trial Emulation Study

Read full text Summarise with VIRAT
Authors: Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Yuya Kimura, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku
+3 more Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated kidney and cardiovascular protection in randomized controlled trials of diabetic kidney disease (DKD). However, the evidence regarding their effect on mortality in older adults remains limited, particularly in real-world clinical practice where multimorbidity and frailty are common. Understanding the mortality benefit of SGLT2 inhibitors in this vulnerable population is of critical importance for clinical decision-making.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104684–104684
Publication date
25 March 2026
Language
EN